A Triumph for Rare Disease Therapy Development

Summary and Comment |
January 7, 2014

A Triumph for Rare Disease Therapy Development

  1. Michael Benatar, MD, MS, PhD

Results of a randomized, double-blind, placebo-controlled trial demonstrate the benefits of diflunisal, a nonsteroidal anti-inflammatory agent, for patients with familial amyloid polyneuropathy.

  1. Michael Benatar, MD, MS, PhD

Amyloid polyneuropathies may be either inherited (familial amyloid polyneuropathy; FAP) or acquired. Autosomal-dominantly inherited mutations in transthyretin (TTR), a thyroxine transport protein, are the most common cause of FAP. Mutations in the TTR gene destabilize its tetrameric structure, promoting dissociation into misfolded amyloidogenic monomers. Knowledge that a second TTR mutation exerts a protective effect by countering the destabilizing effect of pathogenic mutations has led to a search for small molecule kinetic stabilizers of the TTR tetramer as a viable therapeutic alternative to orthotopic liver transplantation. Hot on the heels of promising results published last year for tafamidis, a small molecule that occupies the thyroxine-binding site, investigators now report the results of an international, double-blind, placebo-controlled trial of diflunisal in 130 patients with FAP.

Over a period of 2 years, diflunisal slowed progression of polyneuropathy as measured on a 270-point scale, the Neuropathy Impairment Score plus 7 nerve tests (NIS+7). Using multiple imputation (a statistical approach necessitated by the high rate of loss to follow-up), the NIS+7 score increased (i.e., worsened) significantly more in the placebo group than in the diflunisal group (by 25 points vs. by 8.7 points). The difference of 16.3 points favoring diflunisal exceeds criteria defined by the International Peripheral Nerve Society for clinically meaningfulness. The benefits of diflunisal were also evident on a host of secondary outcome measures, and diflunisal was very well tolerated.


The major limitation of this trial was the substantial loss to follow-up. Of the 130 patients randomized, baseline and 2-year data were available from only 68 patients (28 placebo recipients and 40 diflunisal recipients). The authors carefully addressed this problem by using multiple statistical analyses. Therefore, the results convincingly demonstrate the benefits of diflunisal as a safe and low-cost treatment for slowing progression of polyneuropathy in patients with the most prevalent familial amyloid polyneuropathy transthyretin genotypes.

Editor Disclosures at Time of Publication

  • Disclosures for Michael Benatar, MD, MS, PhD at time of publication Royalties Parker-Waichman LLC Editorial boards Cochrane Collaboration; Muscle & Nerve


Your Comment

(will not be published)

Filtered HTML

  • Allowed HTML tags: <a> <em> <strong> <cite> <blockquote> <code> <ul> <ol> <li> <dl> <dt> <dd>
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Do you have any conflict of interest to disclose?
This question is for testing whether you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

* Required

Reader comments are intended to encourage lively discussion of clinical topics with your peers in the medical community. We ask that you keep your remarks to a reasonable length, and we reserve the right to withhold publication of remarks that do not meet this standard.

PRIVACY: We will not use your email address, submitted for a comment, for any other purpose nor sell, rent, or share your e-mail address with any third parties. Please see our Privacy Policy.